The Kanjinti stability study has recently been published in the Generics and Biosimilars Initiative Journal (GaBI Journal) and can be found here:
QCNW-Liverpool completed a large study on the stability and continued potency of patient preparations of the Trastuzumab biosimilar Kanjinti, with the support of Amgen. The study covered a range of concentrations (0.3mg/ml to 21mg/ml) and containers (IV bags and Intermate devices), with the final reports being supplied to NHS Pharmacies within the United Kingdom. If you wish to have access to the full generated reports please request this using the form within the ‘Contact’ section of the website.
Published: 10/02/2022 Published by: Quality Control North West Liverpool
Return to News Page.